Cheli Cohen-Melzer

27 Hamered Street
Tel Aviv, TA 68125, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Obesity in Late Adolescence and Healthcare Costs in Young to Mid-Adulthood.

Obesity in Late Adolescence and Healthcare Costs in Young to Mid-Adulthood.

Journal: Diabetes, obesity & metabolism
Published: December 23, 2025

Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.

Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.

Journal: Diabetes research and clinical practice
Published: November 28, 2024

Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade.

Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade.

Journal: Journal of gastroenterology and hepatology
Published: March 22, 2024

Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.

Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.

Journal: Diabetes, obesity & metabolism
Published: February 23, 2024

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

Journal: JAMA
Published: October 03, 2023

Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study.

Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study.

Journal: JMIR public health and surveillance
Published: June 22, 2023

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: February 27, 2023

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.

Journal: Diabetes, obesity & metabolism
Published: February 27, 2023

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.

Journal: Cardiovascular diabetology
Published: February 25, 2023

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

Journal: Cardiovascular diabetology
Published: February 17, 2023

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider.

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider.

Journal: Journal of clinical medicine
Published: December 04, 2022

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Journal: Diabetes & metabolism
Published: October 07, 2022
Showing 1-12 of 30

Last Updated: 09/26/2026